Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype

Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of Alzheimer’s disease, many patients with less common neurodegenerative pathologies still lack specific laboratory tools. Frontotemporal lobar degeneration (FTLD) is particularly challenging because its molecular subtypes cannot be distinguished noninvasively. A new study shows an ultrasensitive assay that detects a defining biomarker of a key FTLD subtype.

Mass General Brigham (Boston, MA, USA) investigators developed an ultrasensitive test to detect abnormal clumps of TDP-43, the protein that defines the FTLD-TDP subtype. The method, called the digital seed amplification assay (dSAA), arose from collaboration between pathology and neurology teams. According to the study, the approach could improve assignment of the correct molecular pathology in patients and support research and drug development.partitions a patient’s cerebrospinal fluid (CSF) into nanoliter-scale compartments and digitally counts the number of TDP-43 protein “seeds” present under a microscope

The dSAA . To create a biomarker specific to FTLD-TDP, the team adapted a strategy they previously used to detect misfolded alpha-synuclein, which underlies Parkinson disease pathology. This digital counting framework is intended to sensitively capture pathogenic seed activity rather than bulk protein levels.

In an analysis of 30 CSF samples from individuals with FTLD-TDP and 10 from healthy controls, those with FTLD-TDP showed higher concentrations of TDP-43 seeds. Seed levels also correlated with disease severity, indicating that greater symptom burden paralleled higher seed counts. The findings highlight the dSAA’s potential to aid accurate patient selection for clinical trials and to track treatment efficacy or disease progression over time.

Study limitations included the small sample size, the absence of autopsy confirmation of FTLD-TDP, and the lack of comparison cohorts with other dementia pathologies. The authors note that larger studies spanning diverse neurodegenerative conditions and incorporating gold-standard diagnostic autopsy will be important to validate test specificity.

The work was published online in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association on May 5, 2026.

“In this study, we found elevated concentrations of a biomarker that correlates with FTLD-TDP disease severity. This is just a first step, but it’s an important one because it gives us something measurable. Our vision is to create a test to diagnose patients, monitor treatment efficacy in clinical trials, and follow patient progression,” said David R. Walt, Ph.D., of the Mass General Brigham Department of Pathology.

“Much more work is needed to validate this test rigorously, but this study establishes a framework for developing better tools for diagnosing this devastating disease and monitoring molecular pathology among patients with FTLD. Our test is one of several in development across the world which show promise in eventually giving FTD patients an accurate diagnosis, which is necessary for developing an accurate treatment,” said Andrew M. Stern, M.D., Ph.D., a principal investigator with Mass General Brigham Neuroscience Institute.

Related Links
Mass General Brigham